Categories: Latest

Manipal CDC’s new platform makes maiden investment in iGenetic Diagnostics

New Delhi, March 02, 2017: The new partnership between CDC Group Plc, the UK’s Development Finance Institution and the Dr Ranjan Pai-led, Manipal Education and Medical Group (MEMG), to establish alternate formats to deliver “Health Care Beyond Hospitals” announced its maiden investment in iGenetic Diagnostics Private Limited, a rapidly growing pathology company with a wide range of offerings across molecular pathology, genetic investigations as well routine testing.

iGenetic, was conceived in 2013 by a budding set of young private equity professionals turned entrepreneurs, (Arunima Patel, Siddharth Patodia and HomerPaneri) ably guided by a team of strong clinical researchers and scientists. “The company is focussed on developing pioneering investigation techniques in the areas of fertility , cancer and infectious diseases- the prime objective being to make the cost affordable, deliver authentic investigations and create a new benchmark in turn-around times” says Arunima Patel, Founder and CEO. “With the back-up of strong clinical partners and research-driven approach, we believe we will be able to create a robust pipeline of new modalities”

The MEMG CDC partnership’s initial investment will be used by iGenetic to create a pan India footprint with a focus on deepening its presence in Maharashtra, Karnataka, Tamil Nadu, Andhra Pradesh and Telangana, and expanding into central India over time.

There will be an additional emphasis on building scale through acquisitions and partnering with firms /regionally well reputed networks that are currently constrained to grow beyond a certain level due to management and financial limitations. Another key focus area for iGenetic will be to become the preferred investigation partner for pharmaceutical companies and clinical research organizations.

“We need to make significant changes in some of the business practices in the diagnostic space. This requires professional management and patient investors who are willing to weather the time required to change the established practices. The three founders have left very successful careers to set this up this platform. This spirit of risk taking and enterprise to make a lasting difference is very overwhelming. We have great confidence in the Founders and management team. Highest standards of quality, participation in cutting edge research and fair pricing- Manipal’s core principles will govern the manner in which this business will be managed” says Dr Ranjan Pai.

“We need to create a cost efficient access network for advanced diagnostics, so that people in smaller towns and cities, who are currently deprived of such capability or cannot access it in time, can benefit” says Srini Nagarajan of CDC (Head of South Asia)

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

World Diabetes Day Survey: Diabetologists and Endocrinologists demand for AI-Based Training and Upskilling in Diabetes Care

 A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…

4 days ago

Doctors warn diabetes patients about risk of smoking

People who smoke are also at much higher risk of developing diabetes compared to non-smokers…

5 days ago

CPHI & PMEC India Expo: Encouraging affordable solutions in India’s march towards a $130 Billion Pharma Market by 2030

17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…

5 days ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

6 days ago